Advertisement

Pediatric Nephrology

, Volume 31, Issue 6, pp 941–955 | Cite as

Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy

  • Stefanie Weber
  • Katja Strasser
  • Sabine Rath
  • Achim Kittke
  • Sonja Beicht
  • Martin Alberer
  • Bärbel Lange-Sperandio
  • Peter F. Hoyer
  • Marcus R. Benz
  • Sabine Ponsel
  • Lutz T. Weber
  • Hanns-Georg Klein
  • Julia HoefeleEmail author
Original Article

Abstract

Background

Alport syndrome (ATS) is a progressive hereditary nephropathy characterized by hematuria and proteinuria. It can be associated with extrarenal manifestations. In contrast, thin basement membrane nephropathy (TBMN) is characterized by microscopic hematuria, is largely asymptomatic, and is rarely associated with proteinuria and end-stage renal disease. Mutations have been identified in the COL4A5 gene in ATS and in the COL4A3 and COL4A4 genes in ATS and TBMN. To date, more than 1000 different mutations in COL4A5, COL4A3, and COL4A4 are known.

Methods

In this study mutational analysis by exon sequencing and multiplex ligation-dependent probe amplification was performed in a large European cohort of families with ATS and TBMN.

Results

Molecular diagnostic testing of 216 individuals led to the detection of 47 novel mutations, thereby expanding the spectrum of known mutations causing ATS and TBMN by up to 10 and 6 %, respectively, depending on the database. Remarkably, a high number of ATS patients with only single mutations in COL4A3 and COL4A4 were identified. Additionally, three ATS patients presented with synonymous sequence variants that possible affect correct mRNA splicing, as suggested by in silico analysis.

Conclusions

The results of this study clearly broaden the genotypic spectrum of known mutations for ATS and TBMN, which will in turn now facilitate future studies into genotype–phenotype correlations. Further studies should also examine the significance of single heterozygous mutations in COL4A3 and COL4A4 and of synonymous sequence variants associated with ATS.

Keywords

Alport syndrome Thin basement membrane nephropathy Mutational analysis COL4A5 COL4A3 COL4A4 

Notes

Acknowledgments

We sincerely thank the patients and the physicians for participation in this study.

Compliance with ethical standards

Approval for this study was obtained from the Ethics Committee of the Ludwig-Maximilians University, Munich, Germany. Written informed consent was obtained.

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Noone D, Licht C (2013) An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol 28:1025–1036CrossRefPubMedGoogle Scholar
  2. 2.
    Marcocci E, Uliana V, Bruttini M, Artuso R, Silengo MC, Zerial M, Bergesio F, Amoroso A, Savoldi S, Pennesi M, Giachino D, Rombola G, Fogazzi GB, Rosatelli C, Martinhago CD, Carmellini M, Mancini R, Di Costanzo G, Longo I, Renieri A, Mari F (2009) Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 24:1464–1471CrossRefPubMedGoogle Scholar
  3. 3.
    Nagel M, Nagorka S, Gross O (2005) Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum Mutat 26:60CrossRefPubMedGoogle Scholar
  4. 4.
    Fallerini C, Dosa L, Tita R, Del Prete D, Feriozzi S, Gai G, Clementi M, La Manna A, Miglietti N, Mancini R, Mandrile G, Ghiggeri GM, Piaggio G, Brancati F, Diano L, Frate E, Pinciaroli AR, Giani M, Castorina P, Bresin E, Giachino D, De Marchi M, Mari F, Bruttini M, Renieri A, Ariani F (2014) Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 86:252–257CrossRefPubMedGoogle Scholar
  5. 5.
    Hou P, Chen Y, Ding J, Li G, Zhang H (2007) A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy. Am J Nephrol 27:538–544CrossRefPubMedGoogle Scholar
  6. 6.
    Cook C, Friedrich CA, Baliga R (2008) Novel COL4A3 mutations in African American siblings with autosomal recessive Alport syndrome. Am J Kidney Dis 51:e25–e28CrossRefPubMedGoogle Scholar
  7. 7.
    Longo I, Scala E, Mari F, Caselli R, Pescucci C, Mencarelli MA, Speciale C, Giani M, Bresin E, Caringella DA, Borochowitz ZU, Siriwardena K, Winship I, Renieri A, Meloni I (2006) Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 21:665–671CrossRefPubMedGoogle Scholar
  8. 8.
    Baek JI, Choi SJ, Park SH, Choi JY, Kim CD, Kim YL, Kim UK (2009) Identification of novel variants in the COL4A4 gene in Korean patients with thin basement membrane nephropathy. Indian J Med Res 129:525–533PubMedGoogle Scholar
  9. 9.
    Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takemoto M, Takada M, Shimizu T, Yamashiro Y (2006) Thin basement membrane nephropathy associated with minimal change disease in a 15-year-old boy. Pediatr Nephrol 21:277–280CrossRefPubMedGoogle Scholar
  10. 10.
    Voskarides K, Pierides A, Deltas C (2008) COL4A3/COL4A4 mutations link familial hematuria and focal segmental glomerulosclerosis. glomerular epithelium destruction via basement membrane thinning? Connect Tissue Res 49:283–288CrossRefPubMedGoogle Scholar
  11. 11.
    Tryggvason K, Patrakka J (2006) Thin basement membrane nephropathy. J Am Soc Nephrol 17:813–822CrossRefPubMedGoogle Scholar
  12. 12.
    Cangiotti AM, Sessa A, Meroni M, Montironi R, Ragaiolo M, Mambelli V, Cinti S (1996) Evolution of glomerular basement membrane lesions in a male patient with Alport syndrome: ultrastructural and morphometric study. Nephrol Dial Transplant 11:1829–1834CrossRefPubMedGoogle Scholar
  13. 13.
    Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY (2003) Thin basement membrane nephropathy. Kidney Int 64:1169–1178CrossRefPubMedGoogle Scholar
  14. 14.
    Gubler MC (2007) Diagnosis of Alport syndrome without biopsy? Pediatr Nephrol 22:621–625CrossRefPubMedGoogle Scholar
  15. 15.
    Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013) Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364–375CrossRefPubMedGoogle Scholar
  16. 16.
    Mencarelli MA, Heidet L, Storey H, van Geel M, Knebelmann B, Fallerini C, Miglietti N, Antonucci MF, Cetta F, Sayer JA, van den Wijngaard A, Yau S, Mari F, Bruttini M, Ariani F, Dahan K, Smeets B, Antignac C, Flinter F, Renieri A (2015) Evidence of digenic inheritance in Alport syndrome. J Med Genet 52:163–174CrossRefPubMedGoogle Scholar
  17. 17.
    Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010) Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 21:876–883Google Scholar
  18. 18.
    Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA (2013) COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol 24:1945–1954CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11:649–657Google Scholar
  20. 20.
    Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2002) Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 17:1218–1227CrossRefPubMedGoogle Scholar
  21. 21.
    Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 14:2603–2610CrossRefPubMedGoogle Scholar
  22. 22.
    Study Group Members of the Gesellschaft fur Padiatrische N, Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dotsch J, Muller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494–501CrossRefGoogle Scholar
  23. 23.
    Proesmans W, Van Dyck M (2004) Enalapril in children with Alport syndrome. Pediatr Nephrol 19:271–275CrossRefPubMedGoogle Scholar
  24. 24.
    Rana K, Tonna S, Wang YY, Sin L, Lin T, Shaw E, Mookerjee I, Savige J (2007) Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases. Pediatr Nephrol 22:652–657CrossRefPubMedGoogle Scholar
  25. 25.
    Pierides A, Voskarides K, Athanasiou Y, Ioannou K, Damianou L, Arsali M, Zavros M, Pierides M, Vargemezis V, Patsias C, Zouvani I, Elia A, Kyriacou K, Deltas C (2009) Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis. Nephrol Dial Transplant 24:2721–2729CrossRefPubMedGoogle Scholar
  26. 26.
    Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V, Ioannou K, Athanasiou Y, Patsias C, Alexopoulos E, Pierides A, Kyriacou K, Deltas C (2007) COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 18:3004–3016CrossRefPubMedGoogle Scholar
  27. 27.
    Hertz JM, Thomassen M, Storey H, Flinter F (2015) Clinical utility gene card for: Alport syndrome - update 2014. Eur J Hum Genet. doi: 10.1038/ejhg.2014.254
  28. 28.
    Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J (2004) COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 65:786–790CrossRefPubMedGoogle Scholar
  29. 29.
    Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B, Stavrou C, Gubler MC, Antignac C (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97–106PubMedGoogle Scholar
  30. 30.
    Chatterjee R, Hoffman M, Cliften P, Seshan S, Liapis H, Jain S (2013) Targeted exome sequencing integrated with clinicopathological information reveals novel and rare mutations in atypical, suspected and unknown cases of Alport syndrome or proteinuria. PLoS One 8:e76360CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lemmink HH, Nillesen WN, Mochizuki T, Schroder CH, Brunner HG, van Oost BA, Monnens LA, Smeets HJ (1996) Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 98:1114–1118CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Knebelmann B, Deschenes G, Gros F, Hors MC, Grunfeld JP, Zhou J, Tryggvason K, Gubler MC, Antignac C (1992) Substitution of arginine for glycine 325 in the collagen alpha 5 (IV) chain associated with X-linked Alport syndrome: characterization of the mutation by direct sequencing of PCR-amplified lymphoblast cDNA fragments. Am J Hum Genet 51:135–142PubMedPubMedCentralGoogle Scholar
  33. 33.
    Martin P, Heiskari N, Zhou J, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styrkarsdottir U, Neumann H, Springate J, Shows T, Pettersson E, Tryggvason K (1998) High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 9:2291–2301PubMedGoogle Scholar
  34. 34.
    Beicht S, Strobl-Wildemann G, Rath S, Wachter O, Alberer M, Kaminsky E, Weber LT, Hinrichsen T, Klein HG, Hoefele J (2013) Next generation sequencing as a useful tool in the diagnostics of mosaicism in Alport syndrome. Gene 526:474–477CrossRefPubMedGoogle Scholar
  35. 35.
    Boye E, Flinter F, Zhou J, Tryggvason K, Bobrow M, Harris A (1995) Detection of 12 novel mutations in the collagenous domain of the COL4A5 gene in Alport syndrome patients. Hum Mutat 5:197–204CrossRefPubMedGoogle Scholar
  36. 36.
    Plant KE, Green PM, Vetrie D, Flinter FA (1999) Detection of mutations in COL4A5 in patients with Alport syndrome. Hum Mutat 13:124–132CrossRefPubMedGoogle Scholar
  37. 37.
    Massella L, Gangemi C, Giannakakis K, Crisafi A, Faraggiana T, Fallerini C, Renieri A, Muda AO, Emma F (2013) Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome. Clin J Am Soc Nephrol 8:749–755CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, Hashimoto F, Oka M, Ninchoji T, Ishimori S, Morisada N, Matsunoshita N, Kamiyoshi N, Yoshikawa N, Iijima K (2014) Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int 85:1208–1213CrossRefPubMedGoogle Scholar
  39. 39.
    Wang F, Zhao D, Ding J, Zhang H, Zhang Y, Yu L, Xiao H, Yao Y, Zhong X, Wang S (2012) Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport’s syndrome. J Mol Diagn 14:586–593CrossRefPubMedGoogle Scholar
  40. 40.
    Hertz JM, Juncker I, Marcussen N (2008) MLPA and cDNA analysis improves COL4A5 mutation detection in X-linked Alport syndrome. Clin Genet 74:522–530CrossRefPubMedGoogle Scholar
  41. 41.
    Knebelmann B, Breillat C, Forestier L, Arrondel C, Jacassier D, Giatras I, Drouot L, Deschenes G, Grunfeld JP, Broyer M, Gubler MC, Antignac C (1996) Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome. Am J Hum Genet 59:1221–1232PubMedPubMedCentralGoogle Scholar
  42. 42.
    Gross O, Friede T, Hilgers R, Gorlitz A, Gavenis K, Ahmed R, Durr U (2012) Safety and efficacy of the ACE-inhibitor Ramipril in Alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients. ISRN Pediatr 2012:436046CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Miner JH, Baigent C, Flinter F, Gross O, Judge P, Kashtan CE, Lagas S, Savige J, Blatt D, Ding J, Gale DP, Midgley JP, Povey S, Prunotto M, Renault D, Skelding J, Turner AN, Gear S (2014) The 2014 International Workshop on Alport Syndrome. Kidney Int 86:679–684CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    King K, Flinter FA, Nihalani V, Green PM (2002) Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 111:548–554CrossRefPubMedGoogle Scholar
  45. 45.
    Tryggvason K, Zhou J, Hostikka SL, Shows TB (1993) Molecular genetics of Alport syndrome. Kidney Int 43:38–44CrossRefPubMedGoogle Scholar
  46. 46.
    Anton-Martin P, Aparicio Lopez C, Ramiro-Leon S, Santillan Garzon S, Santos-Simarro F, Gil-Fournier B (2012) Alport syndrome: de novo mutation in the COL4A5 gene converting glycine 1205 to valine. Clin Med Insights Pediatr 6:41–49CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Strachan T, Read AP (1999) Human molecular genetics. Wiley-Liss, New YorkGoogle Scholar
  48. 48.
    Kashtan CE (1999) Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 78:338–360CrossRefGoogle Scholar
  49. 49.
    Slajpah M, Gorinsek B, Berginc G, Vizjak A, Ferluga D, Hvala A, Meglic A, Jaksa I, Furlan P, Gregoric A, Kaplan-Pavlovcic S, Ravnik-Glavac M, Glavac D (2007) Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign familial hematuria. Kidney Int 71:1287–1295CrossRefPubMedGoogle Scholar
  50. 50.
    Demosthenous P, Voskarides K, Stylianou K, Hadjigavriel M, Arsali M, Patsias C, Georgaki E, Zirogiannis P, Stavrou C, Daphnis E, Pierides A, Deltas C, Hellenic Nephrogenetics Research C (2012) X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5. Clin Genet 81:240–248CrossRefPubMedGoogle Scholar
  51. 51.
    Deltas C, Pierides A, Voskarides K (2012) The role of molecular genetics in diagnosing familial hematuria(s). Pediatr Nephrol 27:1221–1231CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Pierides A, Voskarides K, Kkolou M, Hadjigavriel M, Deltas C (2013) X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure. Hippokratia 17:207–213PubMedPubMedCentralGoogle Scholar
  53. 53.
    Barker DF, Denison JC, Atkin CL, Gregory MC (2001) Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet 98:148--160Google Scholar

Copyright information

© IPNA 2016

Authors and Affiliations

  • Stefanie Weber
    • 1
  • Katja Strasser
    • 1
  • Sabine Rath
    • 2
  • Achim Kittke
    • 2
  • Sonja Beicht
    • 2
  • Martin Alberer
    • 3
  • Bärbel Lange-Sperandio
    • 4
  • Peter F. Hoyer
    • 1
  • Marcus R. Benz
    • 5
  • Sabine Ponsel
    • 4
  • Lutz T. Weber
    • 5
  • Hanns-Georg Klein
    • 2
  • Julia Hoefele
    • 2
    • 6
    Email author
  1. 1.Pediatric Nephrology, Pediatrics IIUniversity of Duisburg-EssenEssenGermany
  2. 2.Center for Human Genetics and Laboratory Diagnostics Dr. Klein, Dr. Rost and ColleaguesMartinsriedGermany
  3. 3.Department of Infectious Diseases and Tropical MedicineLudwig-Maximilians UniversityMunichGermany
  4. 4.Pediatric Nephrology, University Children’s HospitalLudwig-Maximilians UniversityMunichGermany
  5. 5.Pediatric NephrologyUniversity Children’s HospitalCologneGermany
  6. 6.Institute of Human GeneticsTechnische Universität MünchenMunichGermany

Personalised recommendations